VIDEO: Study of trastuzumab deruxtecan shows 'impressive' efficacy in HER2-mutated NSCLC
Click Here to Manage Email Alerts
In this video, Edward B. Garon, MD, MS, discusses findings from lung cancer studies, including the DESTINY-Lung01 trial, presented at ESMO 2021.
The phase 2 trial evaluated the use of the HER2 antibody drug conjugate trastuzumab deruxtecan among patients with previously treated HER2-mutated NSCLC.
Researchers determined that there was an overall response rate of 54.9% among 91 patients treated with trastuzumab deruxtecan.
Garon noted that while there were some toxicity issues observed, “in light of the impressive efficacy results, I think that this is something that one would anticipate becoming an established treatment in patients who have been previously treated for HER2-mutant NSCLC.”
Collapse
Li BT, et al. Abstract LBA46. Presented at: European Society for Medical Oncology Congress (virtual meeting); Sept. 16-21, 2021.
Read more about
Click Here to Manage Email Alerts